Back to top
more

Strata Skin Sciences (SSKN)

(Delayed Data from NSDQ)

$0.51 USD

0.51
7,597

-0.01 (-2.78%)

Updated Apr 26, 2024 03:59 PM ET

After-Market: $0.51 0.00 (-0.87%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 252)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New Strong Buy Stocks for February 14th

by Zacks Equity Research

INSP, ALK, SSKN, NVO and TBPH have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.

Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50% and 11.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Tabula Rasa Healthcare (TRHC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -1,366.67% and 4.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Strata Skin Sciences, Inc. (SSKN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -25% and 12.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of 72.73% and 1.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Strata Skin Sciences, Inc. (SSKN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -40% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 11.11% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axonics (AXNX) delivered earnings and revenue surprises of 27.54% and 7.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Strata Skin Sciences, Inc. (SSKN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 33.33% and 0.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Invitae (NVTA) delivered earnings and revenue surprises of -9.46% and 1.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of -10% and 11.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50.00% and -0.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Strata Skin Sciences, Inc. (SSKN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strata Skin Sciences, Inc. (SSKN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50.00% and 14.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Strata Skin Sciences, Inc. (SSKN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strata Skin Sciences, Inc. (SSKN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50.00% and 0.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Strata Skin (SSKN) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Strata Skin (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Strata Skin (SSKN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Strata Skin (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ryan McQueeney headshot

Top 10 Stocks Under $20

by Ryan McQueeney

Today we've highlighted ten stocks that are currently trading for under $20 per share. All of these stocks currently have at least a Zacks Rank #2 (Buy), and a variety of other factors make these companies stand out as having strong upside potential.

    Has Strata Skin Sciences (SSKN) Outpaced Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (SSKN) Outperforming Other Medical Stocks This Year?

      Is Strata Skin Sciences (SSKN) Outperforming Other Medical Stocks This Year?

      by Zacks Equity Research

      Is (SSKN) Outperforming Other Medical Stocks This Year?